Kufs disease due to mutation of CLN6: clinical, pathological and molecular genetic features.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 01 2019
Historique:
received: 06 08 2018
accepted: 02 10 2018
pubmed: 19 12 2018
medline: 21 8 2019
entrez: 19 12 2018
Statut: ppublish

Résumé

Kufs disease is the major adult form of neuronal ceroid lipofuscinosis, but is rare and difficult to diagnose. Diagnosis was traditionally dependent on the demonstration of characteristic storage material, but distinction from normal age-related accumulation of lipofuscin can be challenging. Mutation of CLN6 has emerged as the most important cause of recessive Kufs disease but, remarkably, is also responsible for variant late infantile ceroid lipofuscinosis. Here we provide a detailed description of Kufs disease due to CLN6 pathogenic variants. We studied 20 cases of Kufs disease with CLN6 pathogenic variants from 13 unrelated families. Mean age of onset was 28 years (range 12-51) with bimodal peaks in teenage and early adult life. The typical presentation was of progressive myoclonus epilepsy with debilitating myoclonic seizures and relatively infrequent tonic-clonic seizures. Patients became wheelchair-bound with a mean 12 years post-onset. Ataxia was the most prominent motor feature. Dementia appeared to be an invariable accompaniment, although it could take a number of years to manifest and occasionally cognitive impairment preceded myoclonic seizures. Patients were usually highly photosensitive on EEG. MRI showed progressive cerebral and cerebellar atrophy. The median survival time was 26 years from disease onset. Ultrastructural examination of the pathology revealed fingerprint profiles as the characteristic inclusions, but they were not reliably seen in tissues other than brain. Curvilinear profiles, which are seen in the late infantile form, were not a feature. Of the 13 unrelated families we observed homozygous CLN6 pathogenic variants in four and compound heterozygous variants in nine. Compared to the variant late infantile form, there was a lower proportion of variants that predicted protein truncation. Certain heterozygous missense variants in the same amino acid position were found in both variant late infantile and Kufs disease. There was a predominance of cases from Italy and surrounding regions; this was partially explained by the discovery of three founder pathogenic variants. Clinical distinction of type A (progressive myoclonus epilepsy) and type B (dementia with motor disturbance) Kufs disease was supported by molecular diagnoses. Type A is usually caused by recessive pathogenic variants in CLN6 or dominant variants in DNAJC5. Type B Kufs is usually associated with recessive CTSF pathogenic variants. The diagnosis of Kufs remains challenging but, with the availability of genetic diagnosis, this will largely supersede the use of diagnostic biopsies, particularly as biopsies of peripheral tissues has unsatisfactory sensitivity and specificity.

Identifiants

pubmed: 30561534
pii: 5250431
doi: 10.1093/brain/awy297
doi:

Substances chimiques

CLN6 protein, human 0
Membrane Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

59-69

Subventions

Organisme : Medical Research Council
ID : MC_U12266B
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Auteurs

Samuel F Berkovic (SF)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

Karen L Oliver (KL)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

Laura Canafoglia (L)

Department of Neurophysiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Penina Krieger (P)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

John A Damiano (JA)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

Michael S Hildebrand (MS)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

Michela Morbin (M)

Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Danya F Vears (DF)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

Vito Sofia (V)

Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Section of Neurosciences, University of Catania, Catania, Italy.

Loretta Giuliano (L)

Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Section of Neurosciences, University of Catania, Catania, Italy.

Barbara Garavaglia (B)

Medical Genetics and Neurogenetics Unit, Bicocca Laboratories, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.

Alessandro Simonati (A)

Department of Neuroscience, Biomedicine, Movement-Neurology and Neuropathology, Policlinico GB Rossi, P.le LA Scuro, Verona, Italy.

Filippo M Santorelli (FM)

Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy.

Antonio Gambardella (A)

Institute of Neurology, University Magna Græcia Catanzaro, Italy; Institute of Molecular Bioimaging and Physiology of the National Research Council (IBFM-CNR) Germaneto, CZ, Italy.

Angelo Labate (A)

Institute of Neurology, University Magna Græcia Catanzaro, Italy; Institute of Molecular Bioimaging and Physiology of the National Research Council (IBFM-CNR) Germaneto, CZ, Italy.

Vincenzo Belcastro (V)

Neurology Unit, S. Anna Hospital, Como, Italy.

Barbara Castellotti (B)

Unit Genetics of Neurodegenerative and Metabolic Diseases, IRCCS Foundation C. Besta Neurological Institute, Milan, Italy.

Cigdem Ozkara (C)

Istanbul University-Cerrahpasa, Medical Faculty, Department of Neurology, Istanbul, Turkey.

Adam Zeman (A)

University of Exeter Medical School, St Luke's Campus, Magdalen Road, Exeter EX1 2LU, UK.

Julia Rankin (J)

Clinical Genetics, Royal Devon and Exeter Hospital, Gladstone Road, Exeter, UK.

Sara E Mole (SE)

MRC Laboratory for Molecular Cell Biology and UCL GOS Institute of Child Health, Department of Genetics, Evolution and Environment, University College London, London, UK.

Umberto Aguglia (U)

Department of Medical and Surgical Sciences, University Magna Græcia Catanzaro, Italy.
Institute of Molecular Bioimaging and Physiology of the National Research Council (IBFM-CNR) Germaneto, CZ, Italy.

Michael Farrell (M)

Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.

Sulekha Rajagopalan (S)

Department of Clinical Genetics, Liverpool Hospital, Liverpool, New South Wales Australia.

Alan McDougall (A)

Department of Neurology, Liverpool Hospital, Liverpool, New South Wales Australia.

Susan Brammah (S)

Central Sydney Electron Microscope Unit, Concord Repatriation General Hospital, Concord, New South Wales, Australia.

Frederick Andermann (F)

Epilepsy Research Group, Montreal Neurological Hospital and Institute, Montreal, Quebec, Canada.
Departments of Neurology and Neurosurgery and Paediatrics, McGill University, Montreal, Quebec, Canada.

Eva Andermann (E)

Epilepsy Research Group, Montreal Neurological Hospital and Institute, Montreal, Quebec, Canada.
Departments of Neurology and Neurosurgery and Paediatrics, McGill University, Montreal, Quebec, Canada.

Hans-Henrik M Dahl (HM)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

Silvana Franceschetti (S)

Department of Neurophysiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Stirling Carpenter (S)

Consultant in Neuropathology, Centro Hospitalar São João, Porto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH